NewAmsterdam Pharma Company N.V.
NAMS
$35.26
-$0.59-1.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -332.54% | 55.48% | 57.85% | -86.23% | 64.68% |
| Total Depreciation and Amortization | 128.57% | 136.84% | 246.67% | 292.31% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 833.94% | 959.85% | -114.90% | 785.91% | -32.17% |
| Change in Net Operating Assets | 3,410.71% | -63.48% | 202.11% | -185.45% | 100.48% |
| Cash from Operations | -162.11% | 30.21% | 33.21% | -13.32% | 73.39% |
| Capital Expenditure | 44.00% | 57.89% | 95.84% | 0.00% | -733.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 3,441.33% | -76,041.63% | 841.56% | -2,072,533.33% | -733.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10,058.62% | -26.47% | -95.94% | -- | -68.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -207.96% | -- | -- |
| Cash from Financing | 10,058.62% | -26.47% | -96.71% | -- | -68.82% |
| Foreign Exchange rate Adjustments | -95.11% | 1,070.96% | 251.08% | -252.05% | 383.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.66% | -265.90% | -116.58% | 1,352.88% | 83.51% |